Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors at its meeting held on 12/08/2025 has approved the Re-appointment of Mrs. Ravichandran Chitra (DIN: 07749125) and Mrs. Palamadai Krishnan Sundaresan (DIN: 06954189) as Non-Executive Independent Directors of the Company for a second term of Five consecutive years, subject to apporval of Shareholders at the ensuing Annual General Meeting and Re-appointment of Mr. Bafna Mahaveer Chand as Chief Executive Officer of the Company.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Bafna Pharmaceuticals, at its meeting on August 12, 2025, approved the re-appointment of two Non-Executive Independent Directors — Mrs. Ravichandran Chitra (effective November 12, 2025) and Mr. Palamadai Krishnan Sundaresan (effective September 19, 2025) — each for a second term of five consecutive years, subject to shareholder approval at the upcoming AGM. The Board also approved the re-appointment of Mr. Bafna Mahaveer Chand as Chief Executive Officer for a further five-year term beginning September 10, 2025. All three individuals are continuing in their existing roles, providing leadership continuity. The independent director re-appointments are pending shareholder vote at the next Annual General Meeting.
This is a routine governance announcement signaling management and board continuity at Bafna Pharmaceuticals. No material disruption is expected; shareholder approval for the independent director re-appointments will be sought at the next AGM. Likely neutral to mildly positive sentiment.